POINT ROBERTS, Wash. and KELOWNA, British Columbia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Investorideas.com, a leading investor news resource for cannabis
stocks releases a snapshot looking at CBD and its future role as a pain treatment in healthcare, and how it is being advocated and
embraced by professional athletes.
The World Anti-Doping Agency (WADA) officially removed cannabidiol (CBD) from its Prohibited Substances List effective January
1, 2018 and that has opened up a lot of opportunity for athletes looking for more natural pain treatment solutions and companies in
the space.
In June of this year, The BIG3 basketball league announced they will allow players to use cannabidiol (CBD) as a pain treatment
and for recovery. "The BIG3 is uniquely positioned in professional sports as a player-powered league that looks at our players as
partners not property," BIG3 co-founder and co-CEO Jeff Kwatinetz said in a statement. "As a testament to our relationship with our
players, we listened to their feedback on CBD, as well as feedback from professionals in the regulatory and CBD industry, and
decided to take this major step to support their health."
NFL Players are some of the biggest advocates of the use of CBD for pain and sports injuries and as a Washington Post article explains, “No professional sport has so many outspoken proponents of
marijuana’s medicinal qualities, but then again, no sport is as closely associated with pain and injury.”
Looking at capitalizing on the CBD market opportunity, cannabis life science company Orion Nutraceuticals Inc. (CSE: ORI), just
announce today it is entering the sports medicine CBD market with the addition of Shannon Ford-Smith, sports healthcare and CBD
product expert to its advisory board.
From the news: Shannon Ford-Smith has a uniquely diverse background that includes education, construction, consumer
goods as well as experience building and leading companies in the sports healthcare sector. She has over a decade of experience
building, leading and establishing business direction.
Continued: Throughout her career she has developed deep market insight into the healthcare field. Her recent executive
role at Floyd?s of Leadville as Director of Business Development includes the development of Aeliza (a medical grade CBD product
line) and oversight of the Company?s expansion and growth into the Canadian market, hiring and leading the execution of a common
vision of success while mitigating risk. She spearheaded development of the Aeliza line and personally oversaw every detail, from
product development and formulation, manufacturing, business development, marketing, strategy, as well as bridging the gap between
the medical world and cannabis.
Continued: “We are extremely pleased to add Shannon Ford-Smith to Orion Nutraceutical’s advisory board”, said Jonathan
Fiteni, CEO of Orion. “Her impressive resume includes a strong background in both healthcare and business development. Shannon’s
experience in creating the CBD product line Aeliza will prove instrumental in the creation of Orion’s own sports medicine CBD
product lines.”
Also looking at CBD for pain treatment, Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) and McGill
University announced in August, the launch of an international collaborative medical research project that will
comprehensively examine the therapeutic impact and human health outcomes of cannabidiol (CBD) oil as a therapy for chronic pain and
related anxiety and depression.
From the news: "Based on our extensive experience with more than 60,000 registered Canadian patients, we believe CBD to
be one of the most impactful medical compounds to become legally available to people in need of non-addictive therapies to treat
pain," stated Terry Booth, CEO. "Our support for and involvement with this project underlines Aurora's leadership in the medical
cannabis space, as well as our long-term commitment to a science-based approach to deepen understanding of this amazing
substance.”
Taking a similar path and partnering with a major University, CannTrust Holdings Inc. (TSX: TRST), partnered
with McMaster University on medicinal cannabis research for chronic pain and for designing more effective, safer treatment
protocols in public health policies.
The race is on for companies in the sector and new advancements are being made. In late September, Kalytera Therapeutics,
Inc. (TSX
V: KALY) (OTCQB: KALTF) announced a major step forward in its program to develop the first cannabinoid-derived pain
treatment targeting activation of alpha3 glycine receptors.
“When activated, the alpha3 glycine receptor strongly blocks pain signals from being sent to the brain. Kalytera, and its
research partner, Beetlebung Pharma Ltd. (“BPL”), have carried out a medicinal chemistry program to identify a novel analogue of
cannabidiol (“CBD”) that will block such pain signals via the activation of the alpha3 glycine receptor channel in the spinal cord.
To date, no company has introduced into the market an agent specifically targeting this receptor.”
As far as CBD’s role in sports, it is really just the beginning. According to an article in SportsNet, “Former star NFL running back Ricky Williams thinks cannabis legalization in Canada is “a huge
step forward” towards professional sports leagues like the NFL softening their stances on athletes using marijuana
therapeutically.”
For investors following cannabis stocks, Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC,
NASDAQ, NYSE, ASX Marijuana/Hemp Stocks
About Investorideas.com - News that Inspires Big Investing Ideas
https://www.investorideas.com/About/
Follow us on our Cannabis Social Media
https://www.facebook.com/Investorideaspotcasts/
https://twitter.com/MJInvestorIdeas
https://www.instagram.com/potcasts_investorideas/
This news is published on the Investorideas.com Newswire – News that Inspires big ideas Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation
and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this news article featuring ORI is a paid
for news release on Investorideas.com – third party, Learn more about costs and our services https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all
OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell
cannabis products.
Contact Investorideas.com
800-665-0411
